About CHARSIRE
We focus on developing innovative topical new drugs to address unmet needs in advanced brain and aging diseases.
About CHARSIRE
We focus on developing innovative topical new drugs to address unmet needs in advanced brain and aging diseases
Company Profile
| Company | Charsire Biotechnology Corp. |
| Founded | 2002 |
| Headquarters | 4F-1,No.13,Nanke 2nd Rd.,Xinshi District,Tainan City 744,Taiwan(Tainan Science Park) |
| Paid-in Capital | US$11 Million |
| Chairman | Ms. Chih-Yi Weng |
| Contact | ir@charsire.com.tw |
Revolutionary New Dementia Drug
- Charsire has devoted 20 years to develop the “Multi-Glycan Complex, MGC” from the company’s patented technologies. MGC has applied into medications of three high-impact indications and the clinical results were remarkable.
- With a broad range of application potentials, MGC is a new drug development platform for cerebral and aging associated diseases.
- MGC platform features short R&D time and low R&D costs to greatly accelerate new drug development.
Main New Drugs
- New Alzheimer’s disease and vascular dementia drug, BAC
- New diabetic foot ulcer drug, CSTC1
- New cancer radiodermatitis drug, ACA
Global Market
| Dementia | 2021 | 2030 |
|---|---|---|
| Population | 55M | 78M |
| Market Cap. | $23.9B | $51.5B |
Highlights
- The leader in innovative topical medication
- Invention patents in 16 countries including the US, EU and China
- Our new dementia drug BAC outperforms all competitors
- BAC has completed FDA Phase II clinical trials
Management Team
Chih-Yi Weng
Founder, Chairman & CEO
- 20-year exp. in botanical new drug R&D
- Nutritional biochemistry
- New drug management
- Registered dietitian at Chi Mei Hospital
Teng-Kai Chung
Chief Operating Officer
- Molecular biochemistry
- Clinical study management
- Researcher at NUS and Icahn School of Medicine at Mount Sinai
Chun-Che Lin
Chief R&D Officer
- Chemical analysis and biochip
- Manager at MIRDC
- Postdoctoral researcher at National Cheng Kung University
Chien-Yu Chen
Chief Technology Officer
- Chemical analysis
- Pharmaceutical factory QC control
- CDMO manufacturing control
- R&D manager at PharmaCore Biotech
Tzu-Hui Fang
Chief Financial Officer
- 28-year exp. in international accounting and corporate finance
- Accounting manager at Sinon Corp. and Tainan Enterprises Co.
Advisors
Dr. Chao-Chin Chen
Board Member
- Vice president of R&D at Cordis (a Johnson & Johnson subsidiary)
- Director at Safestitch
- COO at UniMedVM
Dr. Chi-Yu Wu
Board Member
CEO at Proteosome Research Center of Taiwan Genome Medicine National Project
Wen-Nan Li
Board Member
- General manager at Newai Chemical
- VP of Nang Kuang Pharmaceutical Factory manager at Eisai (Japan)
Jeff Chiu
Board Member
- Thunderbird School of Global Management, MBA
- UC, Berkeley Molecular and Cell Biology, B.A.
- Co-founder at Balius EV Pte Ltd.
- Chairman at Qookee Technologies Co., Ltd.
Medical Development Consultant
Dr. Yushan Zhong
Experience
- Botanical Drug Development Consortium – Chief Director
- Development Center for Biotechnology – Associate Director, Institute for Pharmaceutics
- Botanical Drug Development (wound healing of diabetes, cancer and adjuvant therapy, Alzheimer’s disease, liver cancer and liver fibrosis, etc.)
- Establishment of Chinese herbal medicine GACP cultivation and harvesting norms
Dr. Qiongzhi Zhang
Current Position
- Neurology Department-Deputy Director
- Department of Neurology, Kaohsiung Chang Gung Memorial Hospital – General Neurology Attending Physician
- Cognitive neurology, neuroimaging , neurology, early onset dementia treatment, dementia treatment, geriatrics, radiology & medical imaging, carbon monoxide poisoning
Awards & Recognition
| 2021 | National Innovation Award |
| 2021 | International Innovation Award, Enterprise Asia |
| 2021 | Pharmaceutical Technology R&D Award |
| 2021 | Asia-Pacific Award for Quality in the Beauty Industry |
| 2020 | The National Brand YUSHAN Award |
| 2017 | Interview with Pharma Boardroom Magazine for new drug development entering clinical trials |
| 2014 | “The phase II clinical trial of CSTC1, a new botanical drug for treating diabetic foot ulcer healing” was subsidized by the “A+ Industry Innovation R&D Program” of the Ministry of Economic Affairs. |
| 2011 | “Application of lychee waste in the development of functional cosmetic & skin care products” was subsidized by the Council of Agriculture, Executive Yuan |
| 2011 | “Development of high-quality products for legume crops and purple sweet potato” was subsidized by the Council of Agriculture, Executive Yuan |
| 2011 | “Development of CSTC patented extracts for diabetic wound healing products” was subsidized by the Industrialization Technology Promotion Program of Biotechnology R&D Achievements of the Industrial Development Bureau, MOEA |
| 2003 | Institute for Biotechnology and Medicine Industry, Executive Yuan -Finalist |
| 2003 | Won the Gold Diamond Award for Top Commodities of the Consumers Association of the Republic of China |
| 2003 | Won the Golden Peak Award for Outstanding Enterprise and Outstanding Commodity |